Aquinox Pharmaceuticals Nabs $18M Series C Funding
Aquinox Pharmaceuticals Inc., a Vancouver-based company focused on developing novel and targeted small molecule therapeutics for the treatment of inflammatory disease, has secured a US$18 million Series C financing led by Johnson & Johnson Development Corp. New investor Augment Investments participated in the round along with existing investors Baker Brothers Investments, Pfizer Venture Investments and Ventures West Capital. Aquinox has been venture-backed since a 2007 early-stage deal led by Canadian firm Ventures West.
5 April 2013•4 mins read
